Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMET-AMI: Milrinone and Esmolol for Reperfusion Injury in STEMI
NCT02098629Phase 2
Key facts
- Status
- Completed
- Start
- May 2015
- Primary completion
- Mar 2023
- Countries
- 1
- Sponsor
- Shantou University Medical College
- Modality
- Orthosteric Ligands
- Conditions
- myocardial reperfusion injury
01
Overview
Phase 2, randomised, double-blind trial of milrinone and esmolol in myocardial reperfusion injury, sponsored by Shantou University Medical College. Started May 2015; status: completed.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adult patients with STEMI presenting within 12 hours of chest pain onset undergoing PCI, excluding those with prior MI, cardiogenic shock, or significant comorbidities.
04
Registry description
Heart attack is the leading cause of death in the developed world. Following heart attack, re-establishing blood flow in a clogged heart vessel using percutaneous coronary intervention (PCI) is the standard of care. This therapy is called reperfusion therapy. Unfortunately, reperfusion therapy itself poses additional heart muscle damaging effect, a process called reperfusion injury. Excessive reperfusion injury can offset the net benefit of heart vessel blood flow restoration in patients with heart attacks. For those heart attack survivors, massive reperfusion injury can contribute to heart…
Beyond the preview
Go deeper on NCT02098629.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098629.